Syntex phasing out Hamilton Pharma generics subsidiary; Upjohn sticking with Greenstone.
ROCHE/SYNTEX PHASING OUT HAMILTON PHARMA GENERICS BUSINESS "because it no longer fits with the strategic focus in the U.S. of Syntex," the company said Jan. 17. Syntex launched the Hamilton line in late 1993 to introduce generic versions of its flagship nonsteroidal anti-inflammatory drugs Naprosyn (naproxen) and Anaprox (naproxen sodium). The company subsequently introduced versions of the oral contraceptive Levora (levonorgestrel/ethinyl estradiol) and the topical corticosteroid Lidex (fluocinonide). Syntex was acquired by Roche in September.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth